Amylyx Pharmaceuticals (AMLX) Change in Account Payables (2021 - 2026)

Amylyx Pharmaceuticals' Change in Account Payables history runs 6 years deep, the most recent figure standing at $10000.0 for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 99.47% year-over-year to $10000.0 in Q1 2026; TTM through Mar 2026 was -$1.3 million, a 92.27% increase from a year earlier, with the FY2025 full-year figure at $580000.0, up 103.04% from the prior year.
• Change in Account Payables eased to $10000.0 in Q1 2026 per AMLX's latest filing, from $275000.0 in the prior quarter.
• Across five years, Change in Account Payables topped out at $15.8 million in Q4 2023 and bottomed at -$18.4 million in Q3 2023.
• The 5-year median for Change in Account Payables is -$33000.0 (2025), against an average of -$45647.1.
• Across the five-year window, Change in Account Payables surged 2736.16% in 2022 and tumbled 1570.57% in 2023, its largest moves.
• Year by year, Change in Account Payables stood at -$800000.0 in 2022, then surged by 2077.5% to $15.8 million in 2023, then sank by 90.7% to $1.5 million in 2024, then sank by 81.32% to $275000.0 in 2025, then sank by 96.36% to $10000.0 in 2026.
• Per Business Quant, the three latest AMLX Change in Account Payables figures stand at $10000.0 (Q1 2026), $275000.0 (Q4 2025), and -$33000.0 (Q3 2025).